Trial Profile
Phase-III Study of AJM300 in Patients with Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Carotegrast (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Ajinomoto Pharma; EA Pharma
- 06 Oct 2022 Status changed from recruiting to completed.
- 22 Jun 2016 Status changed from active, no longer recruiting to recruiting.
- 20 Jun 2016 Status changed from recruiting to active, no longer recruiting.